Amends title XVIII (Medicare) of the Social Security Act to include information on the coverage of intensive behavioral therapy for obesity in the "Medicare and You Handbook."
Yes but you must also know that Goldilocks is............ now Contrave (Orexigen Therapeutics). ...... preferably covered under their provincial health insurance plan (83% and 71%) ...
Contrave as the Goldilocks of weight-loss pills, meaning the pill's advantage might be the mix of efficacy and safety which sits right in the middle between Vivus' Qsymia and Arena's Belviq:
Goldilocks picks up the big red bowl of porridge (Qsymia) that belongs to Papa Bear (Vivus) but it's much too hot to eat. Goldilocks then picks up the blue bowl of porridge (Belviq) that belongs to Mama Bear (Arena Pharmaceuticals), but it's too cold. Finally, Goldilocks finds a yellow bowl of porridge (Contrave) that belongs to Baby Bear (Orexigen.) She tastes the porridge, and it's just right. Not too hot, not too cold. It's delicious, and she eats the entire bowl.
- Amends title XVIII (Medicare) of the Social Security Act to include information on the coverage of intensive behavioral therapy for obesity in the "Medicare and You Handbook."
Authorizes the Secretary of Health and Human Services (HHS) to allow other physicians, registered dietitians, certified diabetes educators, and instructors trained and certified by the National Diabetes Prevention Lifestyle Coach Training program of the Centers for Disease Control and Prevention (CDC) to provide, and be independently reimbursed for, intensive behavioral therapy for obesity furnished outside of the primary care setting, so long as any such nonphysician provider or instructor furnishing the therapy must communicate any recommendation or treatment plan for an individual to the individual's primary care physicians or practitioner.
Authorizes the Secretary to cover under Medicare part D (Voluntary Prescription Drug Benefit Program) medication for treatment of obesity or for weight loss management for an overweight individual with one or more comorbidities
Bupropion + Naltrexone both are FDA-approved and covered under prescription drug health Insurance coverage.
Bupropion-Zyban ( Smoking-Cessation Benefits / for quitting smoking & can help prevent suicidal thoughts/attempts and provide other important benefits) and Bupropion SR helps your brain cope with withdrawal symptoms- Covered in most of the states under Rx Insurance Coverage- Health Plan
Naltrexone (Vivitrol) ( used for quitting Alcohol) , covered with Health Insurance Coverage
As mentioned above Contrave is based on the two drugs Naltrexone and Bupropion – both of which are extensively tested and are known for their beneficial effects. Of course, these and all drugs across the board are not suitable for everyone, so it’s important to take only under advisement.
•Contrave will be launched with a larger sales force than both Belviq and Qsymia.
•More robust safety data should lead to a larger amount of doctors prescribing Contrave over other options.
•Middle of the road efficacy should be attractive to doctors.
•Contrave could be the first weight loss drug approved in Europe.
The following is an SEC EDGAR document rendered as filed.
Date of Earliest Transaction (MM/DD/YY)
Title of Security
50,000 Price $ 4.782
Lazarus said, noting just two of the risks associated with Contrave. The risk of suicidal thoughts, noted the FDA, is because the drug contains buproprion, an antidepressant, which would signal physicians to use particular cautions when prescribing. It also contains naltrexone, which has been used to treat drug and alcohol dependence. Other listed possible side effects include raised blood pressure and increased heart rate, as well as less significant issues such as nausea, headache, and dry mouth. Qsymia comes with risks that include depression and confusion, while Belviq has been associated with hypoglycemia, hallucinations, depression, painful erections, and a slow heartbeat.
It’s in a different class from the handful of other available anti-obesity drugs, which include five other options such as Qsymia and Belviq
1. American Medical Association began officially recognizing obesity as a disease
2. Contrave works in a different part of the brain, Lazarus explained. In addition to affecting the hypothalamus, as the others Qsymia and Belviq, do, it works in the mesolimbic pathway, also known as the reward pathway. “That’s important,” he explained, “because a lot of people eat out of a sense of rewarding themselves. This turns down that reward system.” He called approval of the drug “awesome,” and said it “gives us a totally new mechanism of treatment.”
Stewragal & Shenzibegal - both is one guy paid by some street vendor on bashing has zero - YES ZERO knowledge on whats going on here.
Orexigen also is pursuing the medicine as a diabetes treatment, which could raises sales in 2020 to $1.2 billion, Andrews said, based on a 65 percent chance it’s cleared for diabetes use.
The FDA had previously rejected Belviq, Qsymia and Contrave on safety concerns, particularly whether the treatments carried heart risks. Qsymia and Belviq are being studied post-approval to determine their effect on the heart.
Orexigen presented an interim analysis of a cardiovascular study the FDA asked for in 2011 to show the drug didn’t present excess risk. That study is expected to be complete in 2016 or 2017 and “could provide a marketing advantage with prescribers from a safety perspective compared to Qsymia and Belviq,” Andrews said.
None of the three weight-loss pills is on the market in Europe. Orexigen’s drug is currently positioned to become the first for sale there in 2015